Why Pharma Serialization Needs a Multi-Market Architecture

Pharmaceutical serialization is no longer a market-by-market compliance exercise. DSCSA is now in full effect in the U.S., the EU's FMD requirements continue to evolve, and markets such as the UAE and Saudi Arabia require their own cryptographic code structures. Running each of these as a standalone system creates real operational delay for any multinational manufacturer. The fix is a Multi-Market Serialization Architecture.

The Problem with Point-to-Point Compliance

Serialization has typically been built market by market. Each time a country introduces. a new mandate, teams deploy a dedicated fix on that market's packaging lines or ERP systems. This creates three recurring problems:

• Shared line, fragmented data: When one packaging line runs products for multiple markets, keeping product and site master data consistent across layer becomes difficult to sustain.
• Endless custom-code: Direct connections to dozens of CMOs, 3PLs, and national verification hubs multiply into a web of one-off integrations that each has to be maintained individually.
• Rigid response to change: A single change to a country's reporting format can stop a line, since the fix has to be built and tested before packaging resumes.

Point-to-point system turns every regulatory change into a production risk.

What Multi-Market Architecture Changes

A multi-market architecture separates packaging operations from the regulatory rules of any single market. Compliance logic doesn't live on the factory floor - it sits in a layer above it, so the physical line stays constant even as regulations shift underneath it.

The packaging line generates the serialized data it always has: unique serial number per unit, plus the case -and pallet-level aggregation that ties units to their parent packaging. The data goes to a central layer where it's matched against product and site master data and normalized to the EPCIS standard (Electronic Product Code Information Services). From there, it's routed to region-specific compliance nodes, each built to the requirements of a specific regulator - a U.S. node structured for DSCSA and EPCIS reporting, an EU node for FMD and EMVO, and so on for every market a product ships to.

The packaging line never needs to know which regulator it's reporting to. Regulatory logic sits entirely in the compliance nodes, so a change to a reporting format is handled there, not on the line. The same structure also handles the different aggregation hierarchies markets require, since unit-case pallet relationships can be reconfigured in the data layer without any change to physical operations.

Architecture vs Patchwork: What Changes

• New market rollout
  • Point-to-point system: months of custom development per site
  • Multi-market architecture: days, using pre-configured compliance nodes
• Partner onboarding
  • Point-to-point system: anew integration cost for every CMO or 3PL added
  • Multi-market architecture: near-zero marginal cost, since new partners connect to the same data layer
• Regulatory updates
  • Point-to-point system: system upgrades and line downtime
  • Multi-market architecture: updated at the compliance-node level, with no disruption to packaging
• Data integrity
  • Point-to-point system: disconnected systems increase the risk of mismatched or missing record
  • Multi-market architecture: a single serialization record shared across markets reduces that risk.

The AltiusHub Approach

AltiusHub builds and operates this architecture as a cloud-native serialization layer, so manufacturing and distribution stay insulated from regulatory change. Whether a product moves through the U.S. market or a chain of international export requirements, AltiusHub handles the translation, validation, and delivery of compliance data.

Rather than responding to each new mandate with one-off fix, pharma companies working with AltiusHub treat serialization as infrastructure: built once, extended as new markets are added.